Mylan N.V.

(MYL) Trade

By |

Profile

Registered in the Netherlands, Mylan is a leading generic drugmaker, with roughly 55 manufacturing and research and development facilities. Although Mylan was formed in 1961, its position as the second- largest generic company was largely attributable to the acquisition of Matrix Laboratories and generics business of Germany-based Merck KGaA. Mylan has a portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines and is predominantly recognized for manufacturing the EpiPen (treatment for anaphylaxis), which was acquired through the Merck KGaA transaction. Unlike its peers, the company has made the most progress on the biosimilar front.

Contact Information

Website: www.mylan.com
Email: InvestorRelations@mylan.com
Main Phone: +44 1707853000
Address: Mosquito Way
Address 2: Building 4, Trident Place
State: Hertfordshire
City / Town: Hatfield
Country: GB
Postal Code: AL10 9UL

Issuer Information

Exchange: NGS
CEO: Heather Bresch
Employees: 35000
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More

Profile

Registered in the Netherlands, Mylan is a leading generic drugmaker, with roughly 55 manufacturing and research and development facilities. Although Mylan was formed in 1961, its position as the second- largest generic company was largely attributable to the acquisition of Matrix Laboratories and generics business of Germany-based Merck KGaA. Mylan has a portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines and is predominantly recognized for manufacturing the EpiPen (treatment for anaphylaxis), which was acquired through the Merck KGaA transaction. Unlike its peers, the company has made the most progress on the biosimilar front.

Contact Information

Website: www.mylan.com
Email: InvestorRelations@mylan.com
Main Phone: +44 1707853000
Address: Mosquito Way
Address 2: Building 4, Trident Place
State: Hertfordshire
City / Town: Hatfield
Country: GB
Postal Code: AL10 9UL

Issuer Information

Exchange: NGS
CEO: Heather Bresch
Employees: 35000
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
$ 14.54 $ 0.17 (1.18%)
Last Price 14.54 Change $ 0.17 Change % 1.18 Tick N/A
Bid 14.50 Bid Size 100.00 Ask 14.73 Ask Size 1,900.00
Open 14.38 High 14.89 Low 14.34 Prev Close 14.37
Last Trade Volume 9.2 mi 52 Wk Hi 23.12 52 Wk Low 12.75
Market Cap 7.5 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 516,946,981.00 EPS (TTM) 0.53 PE Ratio 27.00 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 76
Number of Buys 0 37
Number of Sells 0 39
Net Activity 0 -182124
Last 10 Buys Shares
Joseph C. Maroon 1,000
Joseph C. Maroon 1,000
Robert Cindrich 1,000
Melina E. Higgins 1,000
Melina E. Higgins 1,000
Melina E. Higgins 1,000
Joseph C. Maroon 1,000
Mark W. Parrish 1,000
Wendy Cameron 1,000
Robert Cindrich 1,000
Last 10 Sell Shares
Paul B. Campbell 1,000
Robert J. Coury 1,000
Anthony Mauro 1,000
Rajiv Malik 1,000
Robert J. Coury 1,000
Heather Bresch 1,000
Heather Bresch 1,000
Rajiv Malik 1,000
Anthony Mauro 1,000
Heather Bresch 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 59 59 59 59
Low Target Price Estimate 36 36 36 37
Mean Target Price Estimate 48.07 48.2 48.27 48.2
Standard Deviation 7.29 7.17 7.12 7.07
Date of Most Recent Estimate 06/01/18 05/29/18 05/22/18 06/06/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 9 10 10 9
Moderate Buy 1 1 1 1
Hold 6 6 6 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.78 1.74 1.74 1.85